It will be of great interest to examine this radiotracer and radiolabeled bromo- and iodo-derivatives and test these PARP-1 radiotracers in different PARP-1-enriched cancer models to develop more potent radiotracers with favorable in vivo properties, using talazoparib as a leading scaffold. The gene discussed is PARP1; the disease is cancer.